| Literature DB >> 26583072 |
Gabriela Ruth Mendeluk1, Mariano Isaac Cohen2, Carla Ferreri3, Chryssostomos Chatgilialoglu4.
Abstract
Fatty acid analyses of sperm and erythrocyte cell membrane phospholipids in idiopathic infertile patients evidenced that erythrocyte contents of EPA, DHA, omega-6-omega-3 ratio and arachidonic acid provide a mathematical correspondence for the prediction of EPA level in sperm cells. The erythrocyte lipidomic profile of patients was significantly altered, with signatures of typical Western pattern dietary habits and no fish intake. A supplementation with nutritional levels of EPA and DHA and antioxidants was then performed for 3 months, with the follow-up of both erythrocyte and sperm cell membranes composition as well as conventional sperm parameters. Some significant changes were found in the lipidomic membrane profile of erythrocyte but not in sperm cells, which correspondently did not show significant parameter ameliorations. This is the first report indicating that membrane lipids of different tissues do not equally metabolize the fatty acid elements upon supplementation. Molecular diagnostic tools are necessary to understand the cell metabolic turnover and monitor the success of nutraceuticals for personalized treatments.Entities:
Year: 2015 PMID: 26583072 PMCID: PMC4637148 DOI: 10.1155/2015/670526
Source DB: PubMed Journal: J Nutr Metab ISSN: 2090-0724
Demographic data.
| Patient | Age | Height (cm) | Weight (kg) | Body mass index (kg/m2) | Smoker | Job type | Physical activity | Sport |
|---|---|---|---|---|---|---|---|---|
| 1 | 33 | 170 | 71 | 24.6 | Ex | Architect | Light | No |
| 2 | 31 | 177 | 80 | 25.5 | Ex | Builder | Light | No |
| 3 | 37 | 178 | 83 | 26.2 | No | Driver | No | No |
| 4 | 32 | 172 | 75 | 25.4 | Yes | Teacher | Medium | Yes |
| 5 | 44 | 180 | 95 | 29.3 | No | Mechanic | Light | No |
| 6 | 35 | 171 | 84 | 28.7 | Yes | Gardener | Strong | Yes |
| 7 | 32 | 170 | 65 | 22.5 | No | Stonemason | Light | No |
| 8 | 32 | 169 | 92 | 32.2 | Yes | Seller | No | No |
| 9 | 37 | 164 | 89.4 | 32.2 | Yes | Employee | Light | No |
| 10 | 30 | 185 | 120 | 35.1 | Ex | Operator | Light | No |
Data recorded after the clinical interview: BMI categories: underweight = 18.5; normal weight = 18.5–24.9; overweight = 25–29.9; obesity = BMI of 30 or greater.
Fatty acid profile in erythrocyte membranes.
| FAMEa | Subjects before supplementation | Subjects after supplementation | Optimal interval values |
|
|---|---|---|---|---|
| 16:0 | 26.8 (24.3; 29.8) | 27.3 (24.1; 29) | 17–27 | 0.8326 |
| 18:0 | 20.7 (19.1; 21.4) | 19.5 (16.9; 21.5) | 13–20 | 0.0294 |
| 9cis-16:1 | 0.4 (0.2; 0.6) | 0.6 (0.4; 0.7) | 0.2–0.5 | 0.04 |
| 9cis-18:1 | 15.8 (14.2; 18.3) | 16.0 (14.3; 17.7) | 9–18 | 0.2138 |
| 11cis-18:1 | 1.4 (1.1; 1.7) | 1.3 (1; 1.6) | 0.7–1.3 | 0.4072 |
| 18:2 (omega-6, LA) | 10.3 (9.5; 14.3) | 12.3 (10.0; 14.7) | 9–16 | 0.0044 |
| 20:3 (omega-6, GLA) | 2.0 (1.4; 3.4) | 2.3 (1.3; 3.3) | 1.9–2.4 | 0.863 |
| 20:4 (omega-6, ARA) | 18.1 (16.6; 19.1) | 15.9 (14.0; 19.2) | 13–17 | 0.0092 |
| 20:5 (omega-3, EPA) | 0.4 (0.2; 0.5) | 0.9 (0.6; 1.2) | 0.5–0.9 | 0.0112 |
| 22:6 (omega-3, DHA) | 3.3 (2.2; 4.5) | 4.3 (2.7; 6.3) | 5–7 | 0.0366 |
| Trans-18:1c | 0.2 (0.1; 0.3) | 0.1 (0; 0.2) | 0.1–0.3 | 0.0306 |
| Total SFA | 47.5 (45.0; 50.7) | 46.9 (42.6; 48.5) | 30–45 | 0.1636 |
| Total MUFA | 17.5 (16.1; 20.6) | 18.1 (15.9; 19.7) | 13–23 | 0.2856 |
| Total PUFA | 34.2 (32.4; 38.2) | 35.5 (31.5; 39.8) | 28–39 | 0.3868 |
| SFA/MUFA | 2.7 (2.3; 3.1) | 2.5 (2.4; 3.0) | 1.7–2 | 0.0196 |
| Omega-6/omega-3 | 8.4 (6.2; 13.7) | 5.7 ± (4.5; 9.4) | 3.5–5.5 | 0.01 |
| CV risk indexd | 3.6 (2.6; 4.8) | 5.2 (3.4; 7.2) | 0–4%, high risk | 0.0098 |
The values of the fatty acids are reported as relative percentage (% rel) of the total of 12 fatty acids chosen as representative components of the erythrocyte membrane fatty acids GC analysis as reported in [17]. The values were given as median (min; max). n is the number of subjects. aFAME (fatty acid methyl ester) was determined performing membrane phospholipid extraction, derivatization, and GC analysis as described. The identification of the peaks was performed using authentic samples as described [17, 18]. bThe optimal interval values are reported from [17], as found in a survey of healthy controls reported in the scientific literature and compared with a group of 2500 analyses obtained from the Italian population]. c9-trans-18:1 is considered. dAs described in [19], p values less than 0.05 were considered statistically significant.
Fatty acid profile in sperm cells isolated from the human.
| FAMEa | Samples before supplementation | Samples after supplementation |
|
|---|---|---|---|
| 14:0 | 1.4 (0.83; 1.84) | 1.41 (0.76; 2.55) | 0.61 |
| 16:0 | 33.3 (30.23; 40.78) | 33.79 (24.12; 35.41) | 0.25 |
| 17:0 | 3.21 (1.28; 3.99) | 2.08 (1.25; 2.82) | 0.12 |
| 18:0 | 12.67 (7.55; 16.47) | 10.33 (8.73; 27.07) | 0.75 |
| 20:0 | 2.5 (1.02; 3.05) | 1.54 (1.11; 2.63) | 0.48 |
| 22:0 | 7.67 (2.05; 10.12) | 4.53 (1.78; 12.54) | 0.76 |
| TOT. SFA | 58.03 (52.06; 64.22) | 55.01 (38.72; 66.74) | 0.19 |
| 6c 16:1 | 1.38 (1.0; 1.78) | 1.9 (0.65; 3.98) | >0.99 |
| 9c 16:1 | 3.99 (2.63; 6.31) | 3.68 (1.72; 18.15) | >0.99 |
| 9c 18:1 | 9.85 (6.56; 12.85) | 8.52 (7.2; 15.15) | 0.44 |
| 11c 18:1 | 6.96 (3.77; 9.72) | 4.79 (2.05; 19.27) | 0.87 |
| 20:1 | 3.33 (0.57; 6.79) | 3.83 (1.15; 11.87) | 0.29 |
| 22:1 | 1.25 (0.33; 2.14) | 0.88 (0.26; 1.56) | 0.12 |
| TOT. MUFA | 27.48 (18.96; 30.67) | 26.5 (20.29; 52.94) | 0.54 |
| SFA/MUFA | 2.17 (1.84; 2.81) | 2.17 (0.73; 3.01) | 0.4 |
| 18:2 | 4.21 (3.32; 5.56) | 5.0 (2.5; 6.19) | 0.37 |
| 20:2 | 0.66 (0.16; 1.48) | 0.36 (0.26; 1.25) | 0.48 |
| 20:3 | 1.2 (0.37; 2.44) | 1.21 (0.65; 2.54) | 0.91 |
| 20:4 (arachidonic acid) | 1.54 (0.91; 2.47) | 1.23 (0.63; 3.21) | 0.41 |
| TOT. | 7.54 (6.77; 9.71) | 8.12 (5.0; 10.27) | 0.71 |
| 20:5 (EPA) | 0.46 (0.16; 1.2) | 0.31 (0.17; 0.59) | 0.34 |
| 22:5 | 0.95 (0.44; 2.41) | 0.62 (0.35; 3.72) | 0.15 |
| 22:6 (DHA) | 3.02 (1.46; 19.47) | 3.5 (1.41; 10.4) | 0.71 |
| TOT. | 4.59 (3.02; 22.06) | 4.45 (1.93; 11.79) | 0.78 |
|
| 1.75 (0.34; 2.57) | 1.59 (0.62; 3.3) | 0.46 |
| Trans fatty acid (9t-18:1) | 0.18 (0; 0.65) | 0.12 (0; 0.26) | 0.24 |
The values of the fatty acids are reported as relative percentage (% rel) of the fatty acid peak areas detected in the GC analysis (>98% recognized peaks). The values were given as median (min; max). n is the number of samples. aFAME (fatty acid methyl ester) was determined performing membrane lipid extraction, derivatization, and GC analysis as described [17, 18]. p values less than 0.05 were considered statistically significant.
Sperm parameters.
| Sperm parameter | Before treatment | After treatment |
|
|---|---|---|---|
| Semen volume (mL) | 3.0 (1.7; 7.5) | 3.5 (1.2; 4.5) | 0.52 |
| Sperm concentration (×106/mL) | 1.5 (0.05; 53.6) | 1.1 (0; 64.3) | 0.09 |
| Total sperm count (×106/ejaculate) | 3.28 (0.09; 214.4) | 4.95 (0; 211.75) | 0.85 |
| Progressive motility (%) | 4.5 (0; 36.9) | 3 (0; 20) | 0.32 |
| Total progressive motility (×106/ejaculate) | 0.3 (0; 24.45) | 0.18 (0; 11.63) | 0.60 |
| Normal morphology (%) | 2 (0; 14) | 0 (0; 11) | 0.72 |
| Total normal morphology (×106/ejaculate) | 0 (0; 30.02) | 0 (0; 23.29) | 0.49 |
| Vitality (%) | 55 (0; 89) | 66 (0; 80) | 0.37 |
| Total vitality (×106/ejaculate) | 0.63 (0; 190.82) | 0.8 (0; 156.7) | 0.66 |
| Average path velocity ( | 33.65 (10.5; 66.8) | 20.05 (7.6; 43.3) | 0.04 |
| Straight line velocity ( | 27.2 (5.8; 59.1) | 16.7 (6.3; 36.2) | 0.16 |
| Curvilinear velocity ( | 41.6 (19.6; 83.7) | 27.5 (9.4; 59.2) | 0.04 |
The values are expressed as median (min; max). Sperm assays were performed according to WHO criteria (2010) [20] (n = 9). The kinetic parameters were determined with CASA system (SCA Microptic) (n = 4). p values less than 0.05 were considered statistically significant.